ORIC
Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
CUSIP: 68622P109HealthcareUS3 holders
Total Value
$46.25M
Total Shares
8.29M
Net Share Change
+2.09M
Activity
1 buying1 selling
Investor
Value
Shares
Weight
Change
